Clinical efficacy of iressa combined with radiotherapy in treatment of patients with non-small cell lung cancer and brain metastasis
10.7619/jcmp.201715024
- VernacularTitle:易瑞沙与放疗同期治疗非小细胞肺癌脑转移的临床效果分析
- Author:
Fei TENG
1
;
Miaoling LIU
;
Guimin CUI
;
Yanhong LI
Author Information
1. 河北大学附属医院 放疗科
- Keywords:
iressa;
non-small cell lung cancer;
brain metastasis;
radiotherapy;
gefitinib
- From:
Journal of Clinical Medicine in Practice
2017;21(15):88-91
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of iressa combined with radiotherapy in treatment of patients with non-small cell lung cancer (NSCLC) and brain metastasis.Methods Totally 78 NSCLC patients with brain metastasis were selected and divided into combined group and conventional group.All the patients received whole brain radiotherapy and radiotherapy for local metastasis.The combined group was additionally treated with iressa 250 mg/d, one time per day, and this treatment lasted for more than 8 weeks.Effect and complications were compared between two groups.Results The PR rate, effective rate and disease control rate in the combined group were significantly higher than those in the conventional group, while the disease progression rate was significantly lower than the conventional group (P<0.05).In the combined group, the positive rate of EGFR mutation was 91.30%, which was significantly higher than 62.50% of the negative rate of EGFR mutation (P<0.05).The KPS score, mean survival time and survival rate after treatment in the combined group were significantly better than those in the conventional group (P<0.05).Conclusion Iressa combined with radiotherapy can effectively improve the clinical effect, the survival time and the quality of life in NSCLC patients with brain metastasis.
